Literature DB >> 3979240

Inhibition of canine gastric secretion by the prostanoid Ro 22-6923.

T S Gaginella, R J Bertko, R K Müller, H Gallo-Torres, A C Sullivan.   

Abstract

The synthetic prostanoid, Ro 22-6923, was studied for its effects on canine gastric secretion. Histamine-stimulated acid secretion was inhibited for up to 8 hr after an orally administered dose of 0.25 mg/kg Ro 22-6923. In the Amdrup (modified Pavlov) pouch model, Ro 22-6923 significantly inhibited food-stimulated acid secretion at an oral dose of 0.5 mg/kg. The effect lasted for 4 hr and was of greater intensity than that observed with 5 mg/kg cimetidine. The ED50 for Ro 22-6923 in this model was 0.25 mg/kg and 0.09 mg/kg for oral and intrapouch administration, respectively. Natural prostaglandin E2 was inactive up to 1 mg/kg orally, but had an ED50 of 0.08 mg/kg when administered directly into the pouch. The results indicate that Ro 22-6923 is a potent, long-acting antisecretory drug that may be useful in the therapy of peptic ulcer disease in man.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3979240     DOI: 10.1007/bf01403843

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  17 in total

1.  Effects of an orally administered prostaglandin analogue (16, 16-dimethyl prostaglandin E2) on human gastric secretion.

Authors:  D E Wilson; G Winnan; J Quertermus; P Tao
Journal:  Gastroenterology       Date:  1975-09       Impact factor: 22.682

2.  Effect of oral 16,16-dimethyl-prostaglandin E2 on basal acid output in man.

Authors:  H G Dammann; P Müller; B Simon
Journal:  Br J Clin Pharmacol       Date:  1982-03       Impact factor: 4.335

3.  A simplified procedure for preparing innervated gastric pouches.

Authors:  A Faichney; M S Kim; K Y Lee; W Y Chey
Journal:  Dig Dis Sci       Date:  1980-03       Impact factor: 3.199

Review 4.  Gastric antisecretory and antiulcer properties of PGE2, 15-methyl PGE2, and 16, 16-dimethyl PGE2. Intravenous, oral and intrajejunal administration.

Authors:  A Robert; J R Schultz; J E Nezamis; C Lancaster
Journal:  Gastroenterology       Date:  1976-03       Impact factor: 22.682

5.  Inhibition of stimulated gastric secretion by an orally administered prostaglandin capsule. A study in normal men.

Authors:  D E Wilson; J Quertermus; M Raiser; J Curran; A Robért
Journal:  Ann Intern Med       Date:  1976-06       Impact factor: 25.391

6.  SC-29333: a potent inhibitor of canin gastric secretion.

Authors:  E Z Dajani; D R Driskill; R G Bianchi; P W Collins; R Pappo
Journal:  Am J Dig Dis       Date:  1976-12

7.  Prostaglandins and alkaline secretion from oxyntic, antral, and duodenal mucosa of the dog.

Authors:  S J Konturek; J Tasler; J Bilski; J Kania
Journal:  Am J Physiol       Date:  1983-10

8.  The effect of prostaglandin E2 on duodenal ulcer healing.

Authors:  B Kollberg; P Slezak
Journal:  Prostaglandins       Date:  1982-10

9.  Gastric bicarbonate secretion in humans. Effect of pentagastrin, bethanechol, and 11,16,16-trimethyl prostaglandin E2.

Authors:  M Feldman
Journal:  J Clin Invest       Date:  1983-07       Impact factor: 14.808

10.  Effect of the synthetic prostanoid Ro 22-6923 on gastric secretion and blood flow in Heidenhain pouch dogs.

Authors:  T S Gaginella; R J Bertko; R K Müller; H Gallo-Torres; A C Sullivan
Journal:  J Pharmacol Exp Ther       Date:  1985-01       Impact factor: 4.030

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.